To include your compound in the COVID-19 Resource Center, submit it here.

Avilex debuts to develop compounds for neuropathic pain

Avilex Pharma ApS (Copenhagen, Denmark) debuted with undisclosed seed funding from

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE